Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HTR6 | P50406 | 6/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 7/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650462 | 0.81 | SIRT6 (0.49) | MAPTHTR6SIRT6MAPK1L3MBTL1 | |
| SCHEMBL2650269 | 0.81 | ALK (0.46) | MAPTHTR6SIRT6MAPK1L3MBTL1 | |
| SCHEMBL2661601 | 0.78 | MAPT (0.47) | MAPTSIRT6MAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL2651871 | 0.77 | ALDH1A1 (0.48) | MAPTHTR6SIRT6ALDH1A1 | |
| SCHEMBL2651563 | 0.76 | MAPT (0.44) | MAPTSIRT6MAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL2643420 | 0.76 | L3MBTL1 (0.41) | MAPTMAPK1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1845227 | 0.75 | MAPT (0.70) | MAPTHTR6SIRT6MAPK1L3MBTL1 | |
| SCHEMBL7819742 | 0.75 | KDM4E (0.40) | MAPTL3MBTL1ALDH1A1TDP1 | |
| SCHEMBL2656495 | 0.75 | ALDH1A1 (0.48) | MAPTMAPK1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL7304083 | 0.75 | L3MBTL1 (0.68) | MAPTMAPK1L3MBTL1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934281-B1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-6710044-B2 | Technical field | NEUROSEARCH A/S (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | disclosed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0934281-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017651-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA-A RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | GABRA1, GABRA2, GABRA4 | MAPT 512/4885HTR6 451/4885SIRT6 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.